Cost-effectiveness of lipid-lowering therapy;Kosteneffektivität der lipidsenkenden therapie

Herz

Volumn 26, Issue 8, 2001, Pages 552-560

  Wendland, Guido ^a   Klever Deichert, Gabriele ^a   Lauterbach, Karl ^a  

^a Institut fur Gesundheitsokonomie und Klinische Epidemiologie   (Germany)

Author keywords

CHD risk; Coronary heart disease; Cost effectiveness; Prevention; Statins

Indexed keywords

ANTILIPEMIC AGENT; STATIN;

ARTICLE; CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG EFFICACY; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; MORTALITY; RISK FACTOR; SECONDARY PREVENTION; SOCIAL INSURANCE; TREATMENT PLANNING;

EID: 0035673491     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00002059     Document Type: Article

References (62)

1. Verbreitung der herz-kreislauf-risikofaktoren hypercholesterinämle, übergewicht, hypertonie und rauchen in der bevölkerung (risk factors)
2. Pharmacologic interventions in primary prevention: Lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents
3. Primary prevention of coronary heart disease: Where do we go from here?
4. Applicability of cholesterol-lowering primary prevention trials to a general population: The Framingham Heart Study
5. Mortality after 16 years for participants randomized to the multiple risk factor intervention trial
6. A comparison of economic modelling and clinical trials in the economic evaluation of cholesterol-modifying pharmacotherapy
7. Problems of using modelling in the economic evaluation of health care
8. Gesundheitsökonomie
9. Recommendations of the panel on cost-effectiveness in health and medicine
10. German recommendations for health care economic evaluation studies. Revised version of the Hannover consensus
11. Five-hundred life-saving interventions and their cost-effectiveness
12. Cost-effectiveness league tables: Think of the fans
13. Selection of end points in economic evaluations of coronary-heart-disease interventions
14. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple risk factor intervention trial
15. The prediction of coronary heart disease mortality as a function of major risk factors in over 30 000 men in the Italian RIFLE pooling project. A comparison with the MRFIT primary screenees
16. An updated coronary risk profile. A statement for health professionals
17. The munster heart study (PROCAM). Results of follow-up at 8 years
18. Ten-year follow-up results from the goettingen risk, incidence and prevalence study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men
19. Multivariate prediction of coronary heart disease in the western collaborative group study compared to the findings of the framingham study
20. Baseline risk factors and their association with outcome in the west of Scotland coronary prevention study
21. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S)
22. Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin Survival Study (4s)
23. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air force/Texas coronary atherosclerosis prevention study
24. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
25. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials
26. Prevention of cardiovascular events and death with pravastatinin patients with coronary heart disease and a broad range of initial cholesterol levels
27. Influence of pravastatin and plasma lipids on clinical events in the west of Scotland coronary prevention study (WOSCOPS)
28. Scandinavian simvastatin survival study (4S). Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease
29. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
30. Prevention of coronary heart disease; evidence-based medicine of antilipemic therapy
31. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease
32. Systematic review of randomised controlled trials of multiple risk factor interventions for preventing coronary heart disease
33. In people with no evidence of cardiovascular disease, how effective are interventions aimed at controlling risk factors in reducing all-cause and coronary artery disease mortality?
34. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease
35. Surrogate end points in clinical trials: Are we being misled?
36. A concise review of the cost-effectiveness of coronary heart disease prevention
37. Cost-effectiveness analysis of lipid-modifying therapy in Canada: Comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease
38. Cost-effectiveness analysis of lipid-modifying therapy in Canada: Comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease
39. Economic analysis of secondary prevention of coronary heart disease with simvastatin (Zocor) in Germany
40. Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients
41. Kosten-nutzen-analyse einer evidenzbasierten sekundärprävention koronarer herzkrankheiten durch statine. Eine analyse für Deutschland aus perspektive der sozialversicherung
42. Cost-effectiveness of HMG coenzyme reductase inhibitors. Whom to treat?
43. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
44. Primary prevention of coronary heart disease: Selection of patients for aggressive cholesterol management
45. Air force/Texas coronary atherosclerosis prevention study (afcaps/texcaps): Additional perspectives on tolerability of long-term treatment with lovastatin
46. Incorporating future costs in medical cost-effectiveness analysis: Implications for the cost-effectiveness of the treatment of hypertension
47. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C
48. Preventing fatal diseases increases healthcare costs: Cause elimination life table approach
49. Demographic and epidemiological determinants of healthcare costs in Netherlands: Cost of illness study
50. Statins can help prevent dementia
51. Statins and the risk of dementia
52. Prevention of dementia in randomised double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial
53. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
54. Risk in cardiovascular disease. Merit of using risk reduction rather than absolute risk for lipid lowering drugs
55. Should treatment recommendations for lipid lowering drugs be based on absolute coronary risk or risk reduction?
56. Optimal age for starting lipid lowering treatment. A 10 year risk of 30% should be used
57. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease
58. The predictability of risk factors with respect to incidence and mortality of myocardial infarction and total mortality. A 12-year follow-up of the Oslo Study, Norway
59. Mortality in participants and non-participants of a multifactorial prevention study of cardiovascular diseases: A 28 year follow up of the Helsinki Businessmen Study